0.69

3.42% 0.0101

Aprea Therapeutics Inc (APRE)

Overview News Price History Financials Discussions Forecast Stock Split

Aprea Therapeutics Inc stock is traded at $0.69, with a volume of 17,218. It is up +3.42% in the last 24 hours and down -0.89% over the past month. Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Previous Close:

$0.6799

Open:

$0.679

24h Volume:

17,218

Relative Volume:

0.19

Market Cap:

$8.54M

Revenue:

$123.30K

Net Income/Loss:

$-11.95M

P/E Ratio:

-0.4474

EPS:

-1.5421

Net Cash Flow:

$-12.57M

1W Performance:

+9.13%

1M Performance:

-0.89%

6M Performance:

+17.19%

1Y Performance:

-58.39%

1-Day Range:

$0.67

$0.719

1-Week Range:

$0.6551

$0.78

52-Week Range:

$0.548

$1.75

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name

Aprea Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

215-948-4119

Address

3805 OLD EASTON ROAD, DOYLESTOWN, MA

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

APRE's Discussions on Twitter

Compare APRE vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APRE Aprea Therapeutics Inc	0.69	8.42M	123.30K	-11.95M	-12.57M	-1.5421
VRTX Vertex Pharmaceuticals Inc	515.49	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.31	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	993.60	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.34	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.60	39.31B	5.76B	514.49M	1.10B	4.4813

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Jun-22-20	Initiated	H.C. Wainwright	Neutral
Apr-21-20	Initiated	Robert W. Baird	Outperform
Oct-28-19	Initiated	JP Morgan	Neutral
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight
Oct-28-19	Initiated	RBC Capital Mkts	Outperform

View All

Aprea Therapeutics Inc Stock (APRE) Latest News

Aug 15, 2026

Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 15, 2026

Aug 12, 2026

Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026

Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria

Aug 12, 2026

Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks

Aug 12, 2026

Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India

Aug 12, 2026

Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView

Aug 12, 2026

Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan

Aug 12, 2026

Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times

Aug 12, 2026

Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative

Aug 12, 2026

Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView

Aug 12, 2026

Aug 10, 2026